Israel Cancer Research Fund, Inc.
The Answer to Cancer is Research
Programs and results
What we aim to solve
In today's industrialized world with its adoption of unhealthy lifestyles, more than 20% of the baby boomer population will die of cancer. In one way or another we will all be touched by the disease. The sobering statistics speak for themselves; 39% of women and 41% of men will develop cancer in their lifetime, one in five north Americans will die from the disease.
Our programs
What are the organization's current programs, how do they measure success, and who do the programs serve?
Basic Research into Curing Cancer
Since its inception, ICRF has provided more than $72 million to support innovative studies by Israeli scientists. Our awardees are selected through a rigorous peer-review process that is conducted by a world-class scientific panel. We support individuals at all of the major research institutions in Israel. ICRF-funded researchers have been making significant progress and have been able to develop improved chemotherapies, advanced techniques in bone marrow transplantation, and an enhanced understanding of tumor suppressor genes.
Where we work
External reviews
Our results
How does this organization measure their results? It's a hard question but an important one.
Number of grants and research funding awarded to the institution
This metric is no longer tracked.Totals By Year
Population(s) Served
People with diseases and illnesses
Related Program
Basic Research into Curing Cancer
Type of Metric
Output - describing our activities and reach
Direction of Success
Increasing
Context Notes
The number of cancer research grants awarded to Israeli scientists at Israel institutions performing research.
Estimated number of funding dollars secured for the sector
This metric is no longer tracked.Totals By Year
Population(s) Served
People with diseases and illnesses
Related Program
Basic Research into Curing Cancer
Type of Metric
Output - describing our activities and reach
Direction of Success
Increasing
Context Notes
Monetary value of grants awarded annually for cancer research to Israeli scientists at Israel institutions. Over the last 40 years we have awarded a total of $82.6 million for cancer research.
Number of research studies conducted
This metric is no longer tracked.Totals By Year
Population(s) Served
People with diseases and illnesses
Related Program
Basic Research into Curing Cancer
Type of Metric
Outcome - describing the effects on people or issues
Direction of Success
Increasing
Context Notes
Cancer research studies conducted by Israeli scientists are funded in various stages of their careers. Several scientists funded by ICRF produced advanced research which earned them a noble prize.
Goals & Strategy
Learn about the organization's key goals, strategies, capabilities, and progress.
Charting impact
Four powerful questions that require reflection about what really matters - results.
What is the organization aiming to accomplish?
To harness Israel's educational and scientific resources in the fight against cancer. Our mission: to support cancer research programs in Israel, for the benefit of Israel and all mankind, and to support and encourage Israel's brilliant scientists to remain and conduct their groundbreaking research in Israel.
What are the organization's key strategies for making this happen?
Focus: ICRF is North America's largest non-profit dedicated to supporting cancer research in Israel. ICRF has provided more than $87 million to support cancer research in Israel, funding over 2,700 projects at 24 different Israeli institutions. Virtually all ICRF grants are made to Israeli scientists conducting their research in Israel. Game-Changing Research. Among the scientists funded by ICRF are Drs. Avram Hershko and Aaron Ciechanover, the first Israelis to win a Nobel Prize in the Sciences. Their discovery of the Ubiquitin System led to the development of Velcade, a breakthrough drug used globally to fight multiple myeloma. Gleevec and Doxil are two other highly effective FDA-approved anti-cancer drugs that were developed as a result of ICRF-funded research. Great Value.Your money goes a lot further in Israel. Overhead costs are significantly lower in Israel than they are in the US. Importantly, awards go directly to the researcher without any university or research institute overhead reduction. Careful, Expert Review. ICRF awards are considered high recognition of scientific excellence because of the rigor, thoroughness and objectivity of our selection process modeled on the review process of the US National Institutes of Health. All research requests are carefully reviewed and discussed by members of ICRF's Scientific Review Panel, made up of 40 to 50 of North America's best oncologists and cancer researchers. All About Excellence. ICRF-funded scientists are responsible for numerous significant advances in cancer treatment, including the recent discovery by ICRF supported scientist Dr. Jacob Hanna of the mechanism for producing pluripotent stem cells, dramatically increasing the speed and efficiency of the process and helping to pave the way to innumerable treatments for cancer and many other chronic diseases. Tight Overhead Control. As an institution without walls," ICRF operates with a lean administrative and fundraising budget. For four years in a row, ICRF has increased the share of funding directed to grant making. Charity Navigator, the best-known evaluator of American not-for-profits, gives ICRF high ratings, stating in 2015, that ICRF adheres to good governanceand consistently executes its mission in a fiscally responsible way." Multi-year Support. Scientists attribute special value to our awards which are usually multi-year, enabling the researchers to be assured of continued funding and giving them more time to focus on what they do best brilliant science. Critical Seed Funding. ICRF is proud to have provided funds to support the early work of some of the world's leading cancer researchers well before they came to the attention of more mainstream funders.
Numerous highly respected Israeli scientists, including Dr. Varda Rotter of the Weizmann Institute, Drs. Aaron Ciechanover, Howard Cedar, Ephrat Levy Lahad, and others, acknowledge the critical role ICRF played in helping to launch their research careers.
What are the organization's capabilities for doing this?
Standing against this killer disease is an outstanding group of scientists in Israel. On the cutting edge in the quest for a cure, this group of researchers is supported by the Israel Cancer Research Fund, known as the ICRF. Overhead costs are significantly lower in Israel than in the US. Importantly, awards go directly to the researcher without any university or research institute overhead reduction. ICRF awards are considered high recognition of scientific excellence because of the rigor, thoroughness and objectivity of our selection process – modeled on the review process of the US National Institutes of Health. All research requests are carefully reviewed and discussed by members of ICRF's Scientific Review Panel, made up of 40 to 50 of North America's best oncologists and cancer researchers.
What have they accomplished so far and what's next?
ICRF, a 501(c)(3) organization, is the largest charitable organization outside of Israel solely devoted to supporting cancer research in Israel. ICRF has provided more than $87 million to support innovative studies by Israeli scientists. Awardees are selected through a rigorous peer-review process conducted by a world-class scientific panel in the United States and Canada. ICRF-funded researchers have made major discoveries including enhanced understanding of tumor suppressor genes, production of induced pluripotent stem cells and immunotherapy as well as research leading to life-saving cancer drugs Doxil, Gleevec and Velcade. A gift of $100 or more allows your contribution to be designated towards a specific type of cancer research. Hope for the future. The rate of discovery in cancer research is accelerating and nowhere more than in Israel. For cancer survivors and their families around the world, the recent landscape is almost unrecognizable, with more promising discoveries being made than ever before.
How we listen
Seeking feedback from people served makes programs more responsive and effective. Here’s how this organization is listening.
-
How is your organization using feedback from the people you serve?
To identify and remedy poor client service experiences, To identify bright spots and enhance positive service experiences, To make fundamental changes to our programs and/or operations, To inform the development of new programs/projects, To identify where we are less inclusive or equitable across demographic groups, To strengthen relationships with the people we serve, To understand people's needs and how we can help them achieve their goals
-
Which of the following feedback practices does your organization routinely carry out?
We collect feedback from the people we serve at least annually, We engage the people who provide feedback in looking for ways we can improve in response, We act on the feedback we receive, We tell the people who gave us feedback how we acted on their feedback
-
What challenges does the organization face when collecting feedback?
We don't have any major challenges to collecting feedback
Financials
Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more
about GuideStar Pro.
Operations
The people, governance practices, and partners that make the organization tick.
Connect with nonprofit leaders
SubscribeBuild relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.
Connect with nonprofit leaders
SubscribeBuild relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.
- Analyze a variety of pre-calculated financial metrics
- Access beautifully interactive analysis and comparison tools
- Compare nonprofit financials to similar organizations
Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.
Israel Cancer Research Fund, Inc.
Board of directorsas of 12/01/2023
Ms Bryna Goldberg
Benjamin Bonavida, Ph.D.
Harvey Kaylie
Mark Liss
Lynn H. Ratner, M.D.
Louis Brause
Daniel G. Miller, M.D.
Burton Cohen, M.D.
Judith Sherman
Vera Finkelstein
S. Donald Friedman
Gerald Weiner
Charles Ben-Dyan
Evelyn Bienenfeld
Norman I. Weisman
Leah Susskind
Kamran Hakim
Cynthia Perl
Michael Rosenfelt
Myron Arlen, M.D.
Joel Pelofsky
Lawrence D. Loeb
Rose Blumenthal
Myron Arlen, M.D.
Julie S. Mitnick, M.D.
Alfred Rosenbaum, M.D.
Yashar Hirshaut, M.D.
Michael Walzer
Eve Wald
David N. Weinstein
Kenneth E. Goodman
Richard Edelheit
Harriet Elisofin
Board leadership practices
GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.
-
Board orientation and education
Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes -
CEO oversight
Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes -
Ethics and transparency
Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes -
Board composition
Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes -
Board performance
Has the board conducted a formal, written self-assessment of its performance within the past three years? Yes